Plain-English translation of NCT07071103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for people with advanced cancers that have stopped responding to immunotherapy. The treatment combines a very small, targeted dose of radiation to the intestines with (immune-boosting medications). Early research suggests this combination may help your immune system fight cancer more effectively, even when standard immunotherapy alone has stopped working.
Many patients with advanced cancers develop resistance to immunotherapy, meaning their cancer starts growing again despite treatment. Researchers believe that using low-dose intestinal radiation might change the gut environment in a way that helps this medication work better, offering hope to people for whom other treatments have failed.
You likely qualify if…
You likely don't qualify if…
You will receive one treatment of low-dose radiation targeted to your small intestine, followed by your regular immunotherapy medication within 24 hours. You will continue the immunotherapy as maintenance treatment for up to 2 years according to standard protocols. During the trial, doctors will monitor your cancer using imaging scans, measure how you're doing, and collect blood, stool, and possibly tissue samples to understand how the treatment is working and how it affects your immune system.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China